Long-term Efficacy and Safety of Endoscopic Resection for Patients With Mucosal Adenocarcinoma of the Esophagus

Published:November 22, 2013DOI:https://doi.org/10.1053/j.gastro.2013.11.006

      Background & Aims

      Barrett’s esophagus–associated high-grade dysplasia is commonly treated by endoscopy. However, most guidelines offer no recommendations for endoscopic treatment of mucosal adenocarcinoma of the esophagus (mAC). We investigated the efficacy and safety of endoscopic resection in a large series of patients with mAC.

      Methods

      We collected data from 1000 consecutive patients (mean age, 69.1 ± 10.7 years; 861 men) with mAC (481 with short-segment and 519 with long-segment Barrett’s esophagus) who presented at a tertiary care center from October 1996 to September 2010. Patients with low-grade and high-grade dysplasia and submucosal or more advanced cancer were excluded. All patients underwent endoscopic resection of mACs. Patients found to have submucosal cancer at their first endoscopy examination were excluded from the analysis.

      Results

      After a mean follow-up period of 56.6 ± 33.4 months, 963 patients (96.3%) had achieved a complete response; surgery was necessary in 12 patients (3.7%) after endoscopic therapy failed. Metachronous lesions or recurrence of cancer developed during the follow-up period in 140 patients (14.5%) but endoscopic re-treatment was successful in 115, resulting in a long-term complete remission rate of 93.8%; 111 died of concomitant disease and 2 of Barrett’s esophagus–associated cancer. The calculated 10-year survival rate of patients who underwent endoscopic resection of mACs was 75%. Major complications developed in 15 patients (1.5%) but could be managed conservatively.

      Conclusions

      Endoscopic therapy is highly effective and safe for patients with mAC, with excellent long-term results. In an almost 5-year follow-up of 1000 patients treated with endoscopic resection, there was no mortality and less than 2% had major complications. Endoscopic therapy should become the standard of care for patients with mAC.

      Keywords

      Abbreviations used in this paper:

      APC (argon plasma coagulation), ER (endoscopic resection), HGD (high-grade dysplasia), LSBE (long-segment Barrett’s esophagus), mAC (mucosal adenocarcinoma of the esophagus), PPI (proton pump inhibitor), RFA (radiofrequency ablation)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pohl H.
        • Welch H.G.
        The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
        J Natl Cancer Inst. 2005; 97: 142-146
        • Ell C.
        • May A.
        • Pech O.
        • et al.
        Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer).
        Gastrointest Endosc. 2007; 65: 3-10
        • Pech O.
        • Behrens A.
        • May A.
        • et al.
        Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus.
        Gut. 2008; 57: 1200-1206
        • Chennat J.
        • Konda V.J.A.
        • Ross A.S.
        • et al.
        Complete Barrett’s eradication endoscopic mucosal resection (CBE-EMR): an effective treatment modality for high grade dysplasia (HGD) and intramucosal carcinoma (IMC)—an American single center experience.
        Am J Gastroenterol. 2009; 104: 2684-2692
        • Moss A.
        • Bourke M.J.
        • Hourigan L.F.
        • et al.
        Endoscopic resection for Barrett’s high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit.
        Am J Gastroenterol. 2010; 105: 1276-1283
        • Pouw R.E.
        • Seewald S.
        • Gondrie J.J.
        • et al.
        Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients.
        Gut. 2010; 59: 1169-1177
        • Hvid-Jensen F.
        • Pedersen L.
        • Drewes A.M.
        • et al.
        Incidence of adenocarcinoma among patients with Barrett’s esophagus.
        N Engl J Med. 2011; 365: 1375-1383
        • Spechler S.J.
        • Sharma P.
        • Souza R.F.
        • et al.
        American Gastroenterological Association medical position statement on the management of Barrett's esophagus.
        Gastroenterology. 2011; 140: 1084-1091
        • Koop H.
        • Schepp W.
        • Müller-Lissner S.
        • et al.
        Consensus conference of the DGVS on gastroesophageal reflux.
        Z Gastroenterol. 2005; 43: 163-164
        • Fernando H.C.
        • Murthy S.C.
        • Hofstetter W.
        • et al.
        The Society of Thoracic Surgeons practice guideline series: guidelines for the management of Barrett's esophagus with high-grade dysplasia.
        Ann Thorac Surg. 2009; 87: 1993-2002
        • Wang K.K.
        • Sampliner R.E.
        • Practice Parameters Committee of the American College of Gastroenterology
        Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus.
        Am J Gastroenterol. 2008; 103: 788-797
        • National Institute for Clinical Health and Excellence (NICE) [UK]
        Barrett’s oesophagus — ablative therapy (CG 106).
        National Institute for Clinical Health and Excellence, London, England2010
        • Behrens A.
        • Pech O.
        Barrett esophagus: Treatment without histology—a dangerous affair.
        Nat Rev Gastroenterol Hepatol. 2011; 8: 364-366
      1. Hamilton S.R. Aaltonen L.A. Pathology and genetics of tumours of the digestive system. International Agency for Research on Cancer Press, Lyons, France2000
        • Manner H.
        • Pech O.
        • Heldmann Y.
        • et al.
        Efficiacy, safety and long-term results of endoscopic treatment for early-stage adenocarcinoma of the esophagus with low-risk sm1 invasion.
        Clin Gastroenterol Hepatol. 2013; 11: 630-635
        • Ell C.
        • May A.
        • Gossner L.
        • et al.
        Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus.
        Gastroenterology. 2000; 118: 670-677
        • Ell C.
        • May A.
        • Wurster H.
        The first reusable multiple-band ligator for endoscopic hemostasis of variceal bleeding, nonvariceal bleeding and mucosal resection.
        Endoscopy. 1999; 31: 738-740
        • May A.
        • Gossner L.
        • Behrens A.
        • et al.
        A prospective randomized trial of two different endoscopic resection techniques in 100 consecutive resections in patients with early cancer of the esophagus.
        Gastrointest Endosc. 2003; 58: 167-175
        • Stein H.J.
        • Feith M.
        • Bruecher B.L.D.M.
        • et al.
        Early esophageal squamous cell and adenocarcinoma: pattern of lymphatic spread and prognostic factors for long term survival after surgical resection.
        Ann Surg. 2005; 242: 566-573
        • Hölscher A.H.
        • Bollschweiler E.
        • Schneider P.M.
        • et al.
        Early adenocarcinoma in Barrett’s oesophagus.
        Br J Surg. 1997; 84: 1470-1473
        • Thomas P.
        • Doddoli C.
        • Neville P.
        • et al.
        Esophageal cancer resection in the elderly.
        Eur J Cardiothorac Surg. 1996; 10: 941-946
        • Pech O.
        • Bollschweiler E.
        • Manner H.
        • et al.
        Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers.
        Ann Surg. 2011; 254: 67-72
        • Griffin S.M.
        • Burt A.D.
        • Jennings N.A.
        Lymph node metastasis in early esophageal adenocarcinoma.
        Ann Surg. 2011; 254: 731-736
        • Birkmeyer J.D.
        • Siewers A.E.
        • Finlayson E.V.
        • et al.
        Hospital volume and surgical mortality in the United States.
        N Engl J Med. 2002; 346: 1128-1137
        • Birkmeyer J.D.
        • Stukel T.A.
        • Siewers A.E.
        • et al.
        Surgeon volume and operative mortality in the United States.
        N Engl J Med. 2003; 349: 2117-2127
        • May A.
        • Gossner L.
        • Pech O.
        • et al.
        Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach.
        Eur J Gastroenterol Hepatol. 2002; 14: 1085-1091
        • Heuberger D.
        • Manner H.
        • Ell C.
        • et al.
        How is early Barrett’s cancer currently diagnosed and treated in western Europe? Results of a survey at 52 university hospitals in eight western European countries.
        Z Gastroenterol. 2012; 50: 670-676
        • Manner H.
        • Rabenstein T.
        • Braun K.
        • et al.
        What should we do with the remainder of the Barrett’s segment after endoscopic resection of early Barrett's cancer? Intermediate results of the first prospective-randomized trial on the APC ablation of residual Barrett’s mucosa with concomitant esomeprazole therapy versus surveillance without ablation after ER of early Barrett’s cancer.
        Endoscopy. 2014; 46: 6-12
        • Pouw R.E.
        • Wirths K.
        • Eisendrath P.
        • et al.
        Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia.
        Clin Gastroenterol Hepatol. 2010; 8: 23-29
        • Herrero L.A.
        • van Vilsteren F.G.
        • Pouw R.E.
        • et al.
        Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett’s esophagus longer than 10 cm.
        Gastrointest Endosc. 2011; 73: 682-690
        • Pouw R.E.
        • Gondrie J.J.
        • Rygiel A.M.
        • et al.
        Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia.
        Am J Gastroenterol. 2009; 104: 1366-1373
        • Konda V.J.
        • Ross A.S.
        • Ferguson M.K.
        • et al.
        Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?.
        Clin Gastroenterol Hepatol. 2008; 6: 159-164
        • Sharma P.
        • Dent J.
        • Armstrong D.
        • et al.
        The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria.
        Gastroenterology. 2006; 131: 1392-1399

      Linked Article